Atlas market file · Equity · United States
NRX Pharmaceuticals, Inc.NRXP
- Last close
- 3.58
- Change
- +15.86%
- 96-bar range
- 1.72 – 5.055
- As of
- 7 Aug 2026
NRX Pharmaceuticals, Inc. is a pharmaceutical preparations issuer listed as NRXP on NASDAQ. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
NRXP
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (+72.12% over the window).
Source rail: Yahoo Finance chart API (NRXP). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for NRXP. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
NRXP public profile
Pharmaceutical preparations issuer. NRX Pharmaceuticals, Inc. is connected to current market context, cited company sources and its retained research file.
NRX Pharmaceuticals, Inc. trades as NRXP on NASDAQ. NRX Pharmaceuticals, Inc. (NRXP) has a latest verified close of 3.58, up 15.86%, dated 7 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files NRXP under USA Stocks and Healthcare & Medicine Stocks for browsing.
What changed for NRX Pharmaceuticals, Inc. today
NRx Pharmaceuticals (NRXP) announced the pricing of a $5.7 million public offering in June, touting investor confidence in its NMDA platform for treating suicidal depression and PTSD. However, the company’s 10-Q for Q1 2026 reveals stark financial realities: $1.1 million revenue against a $4.7 million operating loss, with liabilities exceeding assets by $13.8 million. The firm’s cash reserves stood at $6.7 million, down from $11.9 million total assets, as net cash used in operations hit $4.3 million (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1719406/000143774926019576/ex_972122.htm).
NRx’s pipeline includes NRX-100 (preservative-free ketamine) and NRX-101 (D-cycloserine/lurasidone), the latter holding FDA Breakthrough Therapy Designation. Despite this, the company’s recent 8-K filings emphasize future government R&D partnerships rather than near-term revenue. The July 22 disclosure highlights plans for trials combining robotic-enabled Transcranial Magnetic Stimulation with NRX-101, though no commercial sales data exists yet (source: 8-K, 2026-07-22, https://www.sec.gov/Archives/edgar/data/1719406/000143774926024037/nrxp20260722_8k.htm).
Financial risks abound: negative equity, high R&D burn ($1.3 million in Q1), and reliance on dilutive financing. The June offering, led by BTIG and Lucid, diluted existing shareholders without resolving the $25.7 million liability overhang. Chart-wise, NRXP trades in penny-stock territory, with no SEC filings disclosing volume or price levels (source: SEC EDGAR filings, https://www.sec.gov/edgar/browse/?CIK=1719406).
Key uncertainties include FDA approval timelines for NRX-100 and NRX-101, as well as the company’s ability to secure non-dilutive funding. The 8-K filings note ongoing discussions with governmental research bodies, but no binding agreements are disclosed. Investors face a binary: breakthrough therapy success versus cash runway expiration (source: Press Release, June 3, 2026, https://www.sec.gov/Archives/edgar/data/1719406/000143774926019576/ex_972122.htm; 8-K, 2026-06-04, https://www.sec.gov/Archives/edgar/data/1719406/000143774926019576/ex_972572.htm).
Sources & evidence · 10 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
NRXP technical readout
Directional bias down. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on NRXP
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep NRXP research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
NRXP FAQ
What is NRX Pharmaceuticals, Inc. (NRXP)?NRX Pharmaceuticals, Inc. (NRXP) has a latest verified close of 3.58, up 15.86%, dated 7 Aug 2026. Use this page to check the price chart, company context,...
NRX Pharmaceuticals, Inc. (NRXP) has a latest verified close of 3.58, up 15.86%, dated 7 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for NRXP?NRX Pharmaceuticals, Inc. (NRXP) has a latest verified close of 3.58, up 15.86%, dated 7 Aug 2026. It brings the latest available chart, company context, cited sources,...
NRX Pharmaceuticals, Inc. (NRXP) has a latest verified close of 3.58, up 15.86%, dated 7 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files NRXP under USA Stocks and Healthcare & Medicine Stocks for browsing.
How often is the NRXP page updated?The NRXP public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The NRXP public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for NRXP?The NRXP file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:NRXP. SEC EDGAR provides the filing anchor for this issuer. The page separates...
The NRXP file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:NRXP. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on NRXP?Yes. The workstation can open NRXP, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open NRXP, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this NRXP page investment advice?No. The NRXP page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The NRXP page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →